MitoQ for Peripheral Arterial Disease
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it requires that your blood pressure, lipid, and diabetes treatments remain stable for 6 weeks before joining.
Is MitoQ safe for human use?
How does the drug MitoQ differ from other treatments for peripheral arterial disease?
What is the purpose of this trial?
In our research, we are delving into whether taking MitoQ for six months can improve the symptoms and function of people diagnosed with peripheral artery disease, especially those who suffer from leg pain while walking, known as intermittent claudication. We will be checking if MitoQ helps people with claudication walk better, be more active every day, feel better about their lives, and if it enhances the health of their leg muscles.
Research Team
Iraklis Pipinos, MD
Principal Investigator
University of Nebraska
Eligibility Criteria
This trial is for individuals with peripheral artery disease (PAD) or peripheral vascular disease (PVD), who experience leg pain while walking. Participants should be willing to undergo various assessments, including muscle oxygen tests, walking evaluations, quality of life surveys, ankle pressure measurements, and a needle biopsy.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a 24-week regimen of oral dosing with MitoQ or placebo
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- MitoQ
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Nebraska
Lead Sponsor